NCT05208944 2026-04-14
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Recruiting
Clinical Trials
20 trialsNCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
NCT05337163 2025-03-21
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Creative Biosciences (Guangzhou) Co., Ltd.
Completed
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT00073398 2020-05-28
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1/2 Completed
NCT01441128 2019-12-17
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02151149 2018-09-24
ABOUND 70+
Celgene
Phase 4 Completed
NCT02784158 2018-02-06
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Takeda
No longer available
NCT01511081 2017-12-07
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00632203 2017-06-07
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00404924 2016-09-30
ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures
Sanofi
Phase 3 Completed
NCT01317615 2016-03-30
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
Novartis
Phase 4 Completed
NCT01362400 2014-05-19
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT01637376 2014-01-15
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
University of Arkansas
Phase 1 Withdrawn
NCT00596830 2014-01-13
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Pfizer
Phase 3 Terminated
NCT00365183 2013-10-31
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Pharmacyclics LLC.
Phase 2 Terminated
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated
NCT01497041 2011-12-22
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Korean South West Oncology Group
Phase 2 Unknown
NCT00054899 2010-03-24
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
Epimmune
Phase 1 Completed
NCT00102505 2009-04-03
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Pharmacyclics LLC.
Phase 1 Completed